Abstract
We report a case of prolonged half-life of voriconazole due to CYP2C19*2/*2 poor metabolizer genotype in a patient receiving vincristine chemotherapy. Voriconazole was discontinued three days before start of vincristine to avoid a serious drug interaction. Therapeutic drug monitoring and genotyping are valuable tools in managing patients receiving voriconazole and vincristine.
Publication types
-
Case Reports
-
Letter
-
Research Support, N.I.H., Intramural
MeSH terms
-
Adult
-
Antifungal Agents / administration & dosage
-
Antifungal Agents / adverse effects
-
Antifungal Agents / pharmacokinetics*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / pharmacokinetics*
-
Aryl Hydrocarbon Hydroxylases / genetics*
-
Cytochrome P-450 CYP2C19
-
Drug Interactions
-
Genotype
-
Half-Life
-
Humans
-
Male
-
Metabolic Clearance Rate
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / pharmacokinetics*
-
Triazoles / administration & dosage
-
Triazoles / adverse effects
-
Triazoles / pharmacokinetics*
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Vincristine / pharmacokinetics*
-
Voriconazole
Substances
-
Antifungal Agents
-
Antineoplastic Agents
-
Pyrimidines
-
Triazoles
-
Vincristine
-
Aryl Hydrocarbon Hydroxylases
-
CYP2C19 protein, human
-
Cytochrome P-450 CYP2C19
-
Voriconazole